The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may generate novel therapeutic strategies for patients with melanoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shi-Long, Wang, Zhi-Bin, Zhu, Tao, Jiang, Ting, Fei, Jiang-Feng, Liu, Chong, Luo, Chao, Cheng, Yan, Liu, Zhao-Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430041/
https://www.ncbi.nlm.nih.gov/pubmed/34512348
http://dx.doi.org/10.3389/fphar.2021.720619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430041/
https://www.ncbi.nlm.nih.gov/pubmed/34512348
http://dx.doi.org/10.3389/fphar.2021.720619

Ejemplares similares